LIXTE Biotechnology Holdings (NASDAQ: LIXT) has announced a strategic transformation into an AI energy infrastructure equipment and services platform, aiming to address the growing power demands of artificial intelligence and hyperscale data centers. As part of this shift, Stuart D. Porter, founder, managing partner, CEO and chief investment officer of Denham Capital Management LP, has joined the company’s board of directors. The move positions LIXTE to target power equipment and service solutions for AI data-center campuses, distributed power systems and advanced generation technologies.
According to the press release, LIXTE will pursue a strategic acquisition partner for its clinical-stage pharmaceutical and med-tech operations, which focus on cancer treatments. The company’s pharmaceutical pipeline includes LB-100, a first-in-class PP2A inhibitor that has shown tolerability in cancer patients and potential to enhance chemotherapies and immunotherapies. Clinical trials are underway for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additionally, through its subsidiary Liora Technologies Europe Ltd., LIXTE is developing the LiGHT System, an electronically controlled proton therapy system for tumor treatment.
The appointment of Porter brings significant experience in energy infrastructure. Denham Capital is a global private equity firm focused on energy and natural resources. Porter’s expertise is expected to guide LIXTE’s new strategic direction. The company’s board now includes a leader with deep knowledge of capital-intensive infrastructure projects, which is critical for scaling AI energy solutions.
This transformation addresses a pressing industry need: the exponential growth in energy consumption by AI data centers. Hyperscale facilities require reliable, high-capacity power systems, and LIXTE aims to provide equipment and services that support this demand. By pivoting to AI energy infrastructure, the company positions itself at the intersection of two rapidly expanding sectors: artificial intelligence and clean energy technology. The move could have implications for data center operators seeking specialized power solutions, as well as for investors looking for exposure to AI-driven energy markets.
For the pharmaceutical side, LIXTE’s strategy to find a partner for its cancer therapies ensures continued development of LB-100 and the Liora proton therapy system without diverting resources from the new energy focus. This dual approach allows the company to maintain value in its existing assets while pursuing new growth opportunities.
More information about LIXTE’s transformation and board changes is available in the full press release at https://ibn.fm/MVXfg. For updates on LIXTE, visit the company’s newsroom at https://ibn.fm/LIXT.
